Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.34 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.34 |
| ▸ | DRD4 | P21917 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.32 |
| ▸ | EZH2 | Q15910 | 4/20 | 0.32 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.32 |
| ▸ | FSCN1 | Q16658 | 1/20 | 0.32 |
| ▸ | CLPP | Q16740 | 1/20 | 0.32 |
| ▸ | WDR5 | P61964 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1337776 | 0.93 | OPRK1 (0.36) | HTR2AGRM2OPRK1AKR1B1EZH2 | |
| SCHEMBL1338071 | 0.92 | GRM2 (0.36) | HTR2AGRM2AKR1B1DRD4PDE4A | |
| SCHEMBL1336152 | 0.90 | OPRK1 (0.36) | HTR2AGRM2OPRK1AKR1B1DRD4 | |
| SCHEMBL1338132 | 0.90 | SIGMAR1 (0.35) | HTR2AGRM2AKR1B1PDE4APDE4B | |
| SCHEMBL1338219 | 0.89 | AKR1B1 (0.37) | HTR2AGRM2AKR1B1TNIKFSCN1 | |
| SCHEMBL1337037 | 0.88 | TACR1 (0.35) | HTR2AGRM2AKR1B1DRD4PDE4A | |
| SCHEMBL1338058 | 0.87 | MAOB (0.38) | HTR2AGRM2AKR1B1WDR5 | |
| SCHEMBL1338281 | 0.87 | AKR1B1 (0.36) | HTR2AGRM2AKR1B1TNIKWDR5 | |
| SCHEMBL12129232 | 0.86 | GRM2 (0.33) | HTR2AGRM2AKR1B1DRD4TNIK | |
| SCHEMBL1337247 | 0.86 | GRM2 (0.33) | HTR2AGRM2AKR1B1DRD4TNIK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1881825-B1 | HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME (US) | 2013-07-24 | — | — | EP | claimed |
| US-7741315-B2 | HIV integrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-06-22 | — | — | US | claimed |
| US-20090054399-A1 | HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2009-02-26 | — | — | US | claimed |
| EP-1881825-B1 | HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME (US) | 2013-07-24 | — | — | EP | disclosed |
| EP-1881825-B1 | HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME (US) | 2013-07-24 | — | — | EP | disclosed |
| US-20130178468-A1 | HIV INTEGRASE INHIBITORS | VACCA JOSEPH P (US) | 2013-07-11 | — | — | US | disclosed |
| US-20130178468-A1 | HIV INTEGRASE INHIBITORS | VACCA JOSEPH P (US) | 2013-07-11 | — | — | US | disclosed |
| US-20130178468-A1 | HIV INTEGRASE INHIBITORS | VACCA JOSEPH P (US) | 2013-07-11 | — | — | US | disclosed |
| US-8293731-B2 | HIV integrase inhibitors | Merck Sharp + Dohme Corp. (US) | 2012-10-23 | — | — | US | disclosed |
| US-8293731-B2 | HIV integrase inhibitors | Merck Sharp + Dohme Corp. (US) | 2012-10-23 | — | — | US | disclosed |
| US-8293731-B2 | HIV integrase inhibitors | Merck Sharp + Dohme Corp. (US) | 2012-10-23 | — | — | US | disclosed |
| US-20100204201-A1 | HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2010-08-12 | — | — | US | disclosed |
| US-20100204201-A1 | HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2010-08-12 | — | — | US | disclosed |
| US-20100204201-A1 | HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2010-08-12 | — | — | US | disclosed |
| US-7741315-B2 | HIV integrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-06-22 | — | — | US | disclosed |
| US-7741315-B2 | HIV integrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-06-22 | — | — | US | disclosed |
| US-7741315-B2 | HIV integrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-06-22 | — | — | US | disclosed |
| US-20090054399-A1 | HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2009-02-26 | — | — | US | disclosed |
| US-20090054399-A1 | HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2009-02-26 | — | — | US | disclosed |
| US-20090054399-A1 | HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054399-A1 | HIV INTEGRASE INHIBITORS | REV1, POLR1A, POLR2H | HTR2A 4693/4885GRM2 4796/4885OPRK1 1846/4885 |
| US-20100204201-A1 | HIV INTEGRASE INHIBITORS | REV1, CDKN1A, CCNI | HTR2A 4698/4885GRM2 4801/4885OPRK1 1828/4885 |
| US-20130178468-A1 | HIV INTEGRASE INHIBITORS | REV1, CDKN1A, CCNI | HTR2A 4698/4885GRM2 4801/4885OPRK1 1828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.